An Open-label, Long-term Study, with AL-4943A Ophthalmic Solution, 0.2% in Patients with Allergic Conjunctivitis

Registry ID

EUCTR2017-003953-41

Source registry

EUCTR

Phase

PHASE3

Sponsor

Alcon Research Ltd

Last update

2026-08-16

Conditions

• Allergic conjunctivitis

Summary

The purpose of this study was to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

View on source registry